Intravenous delivery of a liposomal formulation of voriconazole improves drug pharmacokinetics, tissue distribution, and enhances antifungal activity
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Voriconazole (VCZ), a triazole with a large spectrum of action is one of the most recommended antifungal agents as the first line therapy against several clinically important systemic fungal infections, including those by Candida albicans. This antifungal has moderate water solubility and exhibits a nonlinear pharmacokinetic (PK) profile. By entrapping VCZ into liposomes, it is possible to circumvent certain downsides of the currently available product such as a reduction in the rate of its metabolization into an inactive form, avoidance of the toxicity of the sulfobutyl ether-beta-cyclodextrin (SBECD), vehicle used to increase its solubility. PKs and biodistribution of VCZ modified by encapsulation into liposomes resulted in improved antifungal activity, due to increased specificity and tissue penetration. In this work, liposomal VCZ resulted in AUC0–24/MIC ratio of 53.51 ± 11.12, whereas VFEND® resulted in a 2.5-fold lower AUC0–24/MIC ratio (21.51 ± 2.88), indicating favorable antimicrobial systemic activity. VCZ accumulation in the liver and kidneys was significantly higher when the liposomal form was used. Protection of the drug from biological degradation and reduced rate of metabolism leads to a 30% reduction of AUC of the inactive metabolite voriconazole-N-oxide (VNO) when the liposomal drug was administered. Liposomal VCZ presents an alternative therapeutic platform, leading to a safe and effective treatment against systemic fungal infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600 · cited 1×
“Different blood circulation times, tissue distribution, and the prevention of biological degradation of the antifungal might influence the efficacy of the drug (Pinto-Alphandary et al., 2000; Pattni et al., 2015).”
BackgroundVirulence factors of Candida albicans
Calderone, R. A., & Fonzi, W. A. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)02094-7 · Cited by 1,331 · cited 1×
“This accumulation, indicated by a higher drug concentration, was shown in liver and kidneys (important target organs of the colonization of this fungal species) (Calderone & Fonzi, 2001; Lionakis et al., 2011; Hohl, 2014).”
BackgroundMaertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01159-9 · Cited by 1,001
Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Roemer, T., & Krysan, D. J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019703 · Cited by 593
Antifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134 · cited 1×
“In clinical trials using azole antimicrobials for the treatment of invasive candidiasis, when this AUC/MIC ratio is >25, treatment success is at least 91% (Lepak & Andes, 2014).”
Background
Cited by
Antifungal Drugs TDM: Trends and Update
Kably, B., Launay, M., Derobertmasure, A., Lefeuvre, S., Dannaoui, E., & Billaud, E. M. (2022) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000952 · Cited by 81
Fahmy, A. M., Hassan, M., El-Setouhy, D. A., Tayel, S. A., & Al-mahallawi, A. M. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.013 · Cited by 45
Nour, E. M., El-Habashy, S. E., Shehat, M. G., Essawy, M. M., El-Moslemany, R. M., & Khalafallah, N. M. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01353-4 · Cited by 41
Metadata
- Authors
- Veloso, D. F. M. C., Benedetti, N. I. G. M., Ávila, R. I., Bastos, T. S. A., Silva, T. C., Silva, M. R. R., Batista, A. C., Valadares, M. C., & Lima, E. M.
- Venue
- Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2018-01-01
- Volume
- 25
- Issue
- 1
- Pages
- 1585-1594
- ISSN
- 1071-7544 (ISSN-L)
- 1521-0464
- OpenAlex
- W2884984240
- Cited by
- 69
- References
- 5
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravenous delivery of a liposomal formulation of voriconazole improves drug pharmacokinetics, tissue distribution, and enhances antifungal activity. https://app.cochat.ai/papers/10.1080/10717544.2018.1492046
- The paper
- Veloso, D. F. M. C., Benedetti, N. I. G. M., Ávila, R. I., Bastos, T. S. A., Silva, T. C., Silva, M. R. R., Batista, A. C., Valadares, M. C., & Lima, E. M. (2018). Intravenous delivery of a liposomal formulation of voriconazole improves drug pharmacokinetics, tissue distribution, and enhances antifungal activity. Drug Delivery. https://doi.org/10.1080/10717544.2018.1492046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.